{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=56", "query": { "condition": "Gastrointestinal Carcinoma", "page": 56 }, "page_size": 10 }, "pagination": { "page": 56, "page_size": 10, "total_count": 2730, "total_pages": 273, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=57&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=55&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T07:18:01.767Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05229900", "title": "A Study of SGN-ALPV in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms", "Endometrial Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Stomach Neoplasms", "Gastroesophageal Junction Carcinoma", "Uterine Cervical Neoplasms", "Testicular Neoplasms" ], "interventions": [ { "name": "SGN-ALPV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2022-04-21", "completion_date": "2023-12-13", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-10-17T07:18:01.767Z", "location_count": 7, "location_summary": "Fresno, California • New Haven, Connecticut • Wellington, Florida + 4 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Wellington", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05229900" }, { "nct_id": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Uveal Melanoma", "Cutaneous Melanoma", "Non-Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "TBio-4101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Turnstone Biologics, Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 31, "start_date": "2023-01-17", "completion_date": "2025-02-24", "has_results": false, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-10-17T07:18:01.767Z", "location_count": 11, "location_summary": "Irvine, California • Hollywood, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05576077" }, { "nct_id": "NCT00913757", "title": "A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Carcinoma, Hepatocellular", "Liver Cirrhosis, Alcoholic", "Hepatitis, Alcoholic", "Hepatitis, Chronic", "Hepatitis, Viral, Human" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 1871, "start_date": "2009-07-01", "completion_date": "2020-05-01", "has_results": false, "last_update_posted_date": "2020-05-04", "last_synced_at": "2026-10-17T07:18:01.767Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00913757" }, { "nct_id": "NCT04175912", "title": "Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cholangiocarcinoma", "Metastatic Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Cholangiocarcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-03-16", "completion_date": "2027-09-03", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-17T07:18:01.767Z", "location_count": 419, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04175912" }, { "nct_id": "NCT07281716", "title": "Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "Nadunolimab", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dan Feng", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-12-01", "completion_date": "2028-12-15", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-10-17T07:18:01.767Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07281716" }, { "nct_id": "NCT07554521", "title": "A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Unresectable Gastric Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Advanced Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-04-30", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T07:18:01.767Z", "location_count": 9, "location_summary": "Bullhead City, Arizona • Cerritos, California • Los Angeles, California + 6 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07554521" }, { "nct_id": "NCT00086567", "title": "Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fallopian Tube Cancer", "Peritoneal Neoplasms", "Epithelial Ovarian Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 119, "start_date": "2005-12-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-17T07:18:01.767Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • Evanston, Illinois + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00086567" }, { "nct_id": "NCT00877071", "title": "LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "LC Bead loaded with doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2008-11", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2016-03-11", "last_synced_at": "2026-10-17T07:18:01.767Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877071" }, { "nct_id": "NCT00669136", "title": "Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Hepatoma", "Liver Cancer, Adult", "Liver Cell Carcinoma", "Liver Cell Carcinoma, Adult", "Cancer of Liver", "Cancer of the Liver", "Cancer, Hepatocellular", "Hepatic Cancer", "Hepatic Neoplasms", "Hepatocellular Cancer", "Liver Cancer", "Neoplasms, Hepatic", "Neoplasms, Liver" ], "interventions": [ { "name": "AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lisa H. Butterfield, Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 2, "start_date": "2009-06", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-10-17T07:18:01.767Z", "location_count": 2, "location_summary": "Los Angeles, California • Pittsburgh, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00669136" }, { "nct_id": "NCT01300533", "title": "A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Cancer", "Solid Tumors" ], "interventions": [ { "name": "BIND-014", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BIND Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2011-01", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-02-09", "last_synced_at": "2026-10-17T07:18:01.767Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "Detriot", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01300533" } ] }